SCHEMBL24601727

CCC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)COCCOCCOCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C

nearest known ligand 0.60

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	13/20	0.60

▸	GCGR	P47871	9/20	0.60

▸	GIPR	P48546	6/20	0.60

▸	CCKBR	P32239	1/20	0.57

▸	PRLHR	P49683	6/20	0.56

▸	CXCR4	P61073	1/20	0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL26346380	1.00	GLP1R (0.60)	GLP1RGCGRGIPRCCKBRPRLHR
SCHEMBL22423719	0.85	RAMP3 (0.56)	GLP1RGCGR
SCHEMBL12984646	0.80	RAMP3 (0.63)	—
SCHEMBL31182766	0.79	PTH1R (0.73)	GLP1RCXCR4
SCHEMBL31332016	0.78	MC4R (0.71)	GLP1RCXCR4
SCHEMBL30409891	0.78	EED (0.58)	GLP1RGCGRGIPRCXCR4
SCHEMBL31182484	0.77	KEAP1 (0.72)	GLP1RGCGRGIPRCXCR4
SCHEMBL26209740	0.77	APLNR (0.50)	CXCR4
SCHEMBL30439709	0.77	CXCL8 (0.59)	GLP1RGCGRCXCR4
SCHEMBL30658352	0.77	CXCR4 (0.71)	GLP1RCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20220211648-A1	COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY	INDI MOLECULAR, INC.	2022-07-07	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20220211648-A1	COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY	TP53, BAX, RNASE1	GLP1R 4422/4885GCGR 3014/4885GIPR 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.